U.S. flag An official website of the United States government
  1. Home
  2. Vaccines, Blood & Biologics
  3. Cellular & Gene Therapy Products
  4. CBER Regenerative Medicine Advanced Therapy (RMAT) Approvals
  1. Cellular & Gene Therapy Products

CBER Regenerative Medicine Advanced Therapy (RMAT) Approvals

Data as of March 31, 2021

Application Number Submission Type
and Number
Proprietary Name Established Name Applicant Approval Date Use

BLA 125714

ORIGINAL-1

BREYANZI

lisocabtagene maraleucel

Juno Therapeutics, a Celgene Company

05-Feb-2021

Treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma after at least two prior therapies.

* RMAT designation was enacted in the 21st Century Cures Act on December 13, 2016.


Resources for You

Back to Top